Pertussis Market Expected to rise, 2032 | Serum Institute of India, LG Chem, ILiAD Biotechnologies, Dynavax Technologies, Tianjin CanSino Biotechnology, Faron Pharmaceuticals, Kymab, BioNet

The Pertussis market growth is driven by factors like increase in the prevalence of Pertussis, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Pertussis market report [https://www.delveinsight.com/report-store/pertussis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Pertussis market size, share, Pertussis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Pertussis market size growth forward.

Some of the key highlights from the Pertussis Market Insights Report:

*
Several key pharmaceutical companies, including Serum Institute of India, LG Chem, ILiAD Biotechnologies, Dynavax Technologies, Tianjin CanSino Biotechnology, Faron Pharmaceuticals, Kymab, BioNet, and others, are developing novel products to improve the Pertussis treatment outlook.

*
Pertussis therapies are ADACEL, BOOSTRIX, BPZE1, BK1310/MT-2355, and others.

*
The Pertussis market is anticipated to expand as awareness of the disease grows and advancements in treatment and prevention continue to emerge.

*
In November 2024, researchers from Tulane University introduced a novel nasal vaccine combining traditional pertussis antigens with an innovative adjuvant called T-vant. This adjuvant enhances the immune response specifically in the respiratory tract. Preclinical studies in mice showed that this vaccine effectively eliminated B. pertussis from both the lungs and nasopharynx three weeks post-infection, whereas traditional intramuscular vaccines did not clear the bacteria from the upper respiratory tract. These findings suggest potential for improved prevention of disease transmission.

*
In January 2022, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to BPZE1, a next-generation live-attenuated intranasal pertussis vaccine developed by ILiAD Biotechnologies. BPZE1 aims to address limitations of current vaccines by inducing durable mucosal immunity and reducing nasal colonization, thereby potentially preventing transmission. Clinical trials have shown promising results, including a Phase 2b trial with 300 adult participants demonstrating these benefits.

*
As per DelveInsight analysis, the Pertussis market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Pertussis Market Landscape [https://www.delveinsight.com/sample-request/pertussis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Pertussis Overview

Pertussis, commonly known as whooping cough, is a highly contagious respiratory infection caused by *Bordetella pertussis*. The term "pertussis" translates to "a violent cough." The disease progresses through three stages: catarrhal, paroxysmal, and convalescent.

Diagnosing pertussis accurately and promptly can be challenging. Several diagnostic tests are used, including culture, polymerase chain reaction (PCR), paired sera, and single sera. Each test varies in sensitivity and specificity, with paired sera being the most reliable method.

Vaccination remains the most effective way to prevent pertussis. In the United States, two vaccines-DTaP and Tdap-help protect against the disease. Throughout their lifetime, all adolescents and adults should receive at least three documented doses of a tetanus and diphtheria toxoid-containing vaccine (DTaP, DTP, DT, or Td).

Macrolide antibiotics, such as erythromycin, clarithromycin, and azithromycin, are the primary treatment for pertussis and post-exposure prophylaxis (PEP). While erythromycin has historically been recommended, its side effects have led to lower adherence, prompting increased use of newer macrolides.

Do you know the treatment paradigms for different countries? Download our Pertussis Market Sample Report [https://www.delveinsight.com/report-store/pertussis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Pertussis Epidemiology Insights

*
In 2022, pertussis vaccination coverage in the United States reached around 19 million. The highest vaccination rate was observed among individuals aged 18 and older, with approximately 5 million receiving the vaccine.

Pertussis Epidemiology Segmentation

DelveInsight's Pertussis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Pertussis historical patient pools and forecasted Pertussis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Pertussis Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

*
Pertussis Prevalence

*
Age-Specific Pertussis Prevalence

*
Gender-Specific Pertussis Prevalence

*
Diagnosed and Treatable Cases of Pertussis

Visit for more @ Pertussis Epidemiological Insights [https://www.delveinsight.com/sample-request/pertussis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Pertussis Market Outlook

The most effective way to prevent pertussis is through full immunization. The pertussis vaccine is typically administered alongside diphtheria and tetanus, often combined with poliomyelitis, *Haemophilus influenzae*, and hepatitis B. Three main vaccine formulations are available: DTaP, Tdap, and Td. Before 1980, whole-cell pertussis vaccines (wPV) were widely used, but they were associated with rare but serious side effects, including prolonged crying, febrile seizures, and, in very rare cases, hypotonic-hyporesponsive episodes. To improve safety, acellular pertussis vaccines (aPVs) were later developed. While aPVs have a better safety profile, their efficacy is slightly lower than that of wPVs. Despite this, wPVs remain the most commonly used pertussis vaccine worldwide, mainly due to the high cost of aPVs, which makes them less accessible in low-resource countries.

Treatment for pertussis primarily involves supportive care, including oxygen therapy, suctioning, hydration, and minimizing exposure to respiratory irritants. In severe cases, parenteral nutrition may be required due to the prolonged nature of the illness. Antibiotics are commonly used to treat whooping cough, primarily to reduce bacterial transmission. Erythromycin (40-50 mg/kg per day, up to a maximum of 2 g per day, divided into 2-3 doses) is the first-line treatment. Alternative antibiotics include azithromycin (10 mg/kg on Day 1, followed by 5 mg/kg on Days 2-5) and clarithromycin (15 mg/kg per day in two divided doses).

The U.S. Food and Drug Administration (FDA) has approved 12 combination vaccines to protect against diphtheria and tetanus, including Pentaxim, Infanrix, Pentacel, and Vaxelis. While pertussis vaccination programs have been highly effective across Europe, studies indicate that the disease remains prevalent among middle-aged adults in several European countries.

Pertussis Marketed Drugs

*
ADACEL: Sanofi Pasteur

*
BOOSTRIX: GlaxosmithKline

Pertussis Emerging Drugs

*
BPZE1: ILiAD Biotechnologies

*
BK1310/MT-2355: Mitsubishi Tanabe Pharma Corporation

Pertussis Key Companies

*
Serum Institute of India, LG Chem, ILiAD Biotechnologies, Dynavax Technologies, Tianjin CanSino Biotechnology, Faron Pharmaceuticals, Kymab, BioNet, and others

For more information, visit Pertussis Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/pertussis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Pertussis Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Pertussis, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Pertussis epidemiology in the 7MM

*
Pertussis marketed and emerging therapies

*
Pertussis companies

*
Pertussis market drivers and barriers

Table of Contents:

1 Pertussis Market Key Comprehensive Insights

2 Pertussis Market Report Introduction

3 Competitive Intelligence Analysis for Pertussis

4 Pertussis Market Analysis Overview at a Glance

5 Executive Summary of Pertussis

6 Pertussis Epidemiology and Market Methodology

7 Pertussis Epidemiology and Patient Population

8 Pertussis Patient Journey

9 Pertussis Treatment Algorithm, Pertussis Current Treatment, and Medical Practices

10 Key Endpoints in Pertussis Clinical Trials

11 Pertussis Marketed Therapies

12 Pertussis Emerging Therapies

13 Pertussis: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Pertussis

16 Pertussis Market Key Opinion Leaders Reviews

18 Pertussis Market Drivers

19 Pertussis Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Pertussis Epidemiology 2032

DelveInsight's "Pertussis - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Pertussis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Pertussis Pipeline 2024

"Pertussis Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Pertussis market. A detailed picture of the Pertussis pipeline landscape is provided, which includes the disease overview and Pertussis treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pertussis-market-expected-to-rise-2032-serum-institute-of-india-lg-chem-iliad-biotechnologies-dynavax-technologies-tianjin-cansino-biotechnology-faron-pharmaceuticals-kymab-bionet]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.